KR20200115583A - Cdk4 및 cdk6 억제제로서의 2h-인다졸 유도체 및 그의 치료 용도 - Google Patents

Cdk4 및 cdk6 억제제로서의 2h-인다졸 유도체 및 그의 치료 용도 Download PDF

Info

Publication number
KR20200115583A
KR20200115583A KR1020207024587A KR20207024587A KR20200115583A KR 20200115583 A KR20200115583 A KR 20200115583A KR 1020207024587 A KR1020207024587 A KR 1020207024587A KR 20207024587 A KR20207024587 A KR 20207024587A KR 20200115583 A KR20200115583 A KR 20200115583A
Authority
KR
South Korea
Prior art keywords
compound
solvate
pharmaceutically acceptable
hydrogen
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207024587A
Other languages
English (en)
Korean (ko)
Inventor
마이클 니콜라스 그레코
마이클 존 코스탄조
지롱 펭
돈 장
Original Assignee
베타 파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베타 파마, 인크. filed Critical 베타 파마, 인크.
Publication of KR20200115583A publication Critical patent/KR20200115583A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207024587A 2018-01-29 2019-01-29 Cdk4 및 cdk6 억제제로서의 2h-인다졸 유도체 및 그의 치료 용도 Withdrawn KR20200115583A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862623516P 2018-01-29 2018-01-29
US62/623,516 2018-01-29
PCT/US2019/015547 WO2019148161A1 (en) 2018-01-29 2019-01-29 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
KR20200115583A true KR20200115583A (ko) 2020-10-07

Family

ID=67394794

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207024587A Withdrawn KR20200115583A (ko) 2018-01-29 2019-01-29 Cdk4 및 cdk6 억제제로서의 2h-인다졸 유도체 및 그의 치료 용도

Country Status (15)

Country Link
US (1) US11352341B2 (cg-RX-API-DMAC10.html)
EP (1) EP3746072B1 (cg-RX-API-DMAC10.html)
JP (1) JP7337395B2 (cg-RX-API-DMAC10.html)
KR (1) KR20200115583A (cg-RX-API-DMAC10.html)
CN (1) CN111989099A (cg-RX-API-DMAC10.html)
AU (1) AU2019211491B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020015405A2 (cg-RX-API-DMAC10.html)
CA (1) CA3088381A1 (cg-RX-API-DMAC10.html)
EA (1) EA202091450A1 (cg-RX-API-DMAC10.html)
IL (1) IL275948A (cg-RX-API-DMAC10.html)
MX (1) MX2020007959A (cg-RX-API-DMAC10.html)
PH (1) PH12020551155A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202006748RA (cg-RX-API-DMAC10.html)
TW (1) TW201940166A (cg-RX-API-DMAC10.html)
WO (1) WO2019148161A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
JP2020527588A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドNuvation Bio Inc. アデノシンアンタゴニストとしてのヘテロ環式化合物
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
AU2019289176B2 (en) * 2018-06-18 2026-02-19 Adelaide university Gremlin-1 antagonist for the prevention and treatment of cancer
WO2020150674A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
US20220079944A1 (en) * 2019-01-29 2022-03-17 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
TW202521536A (zh) * 2019-05-05 2025-06-01 美商基尼特奇公司 Cdk抑制劑
US12570633B2 (en) 2020-06-22 2026-03-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Preparation method for CDK4/6 inhibitor
US20230416271A1 (en) * 2020-11-26 2023-12-28 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. Heteroarylquinazoline compounds as protein kinase inhibitors
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
DE602004017474D1 (de) 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
JPWO2006008874A1 (ja) * 2004-05-21 2008-05-01 萬有製薬株式会社 アミノチアゾ−ル骨格を有するCdk4、6選択的阻害剤
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
AU2009284098B2 (en) * 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
RU2670762C2 (ru) * 2013-12-31 2018-10-25 Хуаньчжу Фарма Ко., Лтд. Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака
WO2016014904A1 (en) * 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
US9969719B2 (en) * 2015-03-11 2018-05-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
CN107286134B (zh) * 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2,4-二取代嘧啶衍生物作为cdk抑制剂及其应用

Also Published As

Publication number Publication date
CA3088381A1 (en) 2019-08-01
CN111989099A (zh) 2020-11-24
IL275948A (en) 2020-08-31
JP7337395B2 (ja) 2023-09-04
AU2019211491B2 (en) 2024-03-14
EP3746072B1 (en) 2023-04-12
EP3746072A4 (en) 2021-06-02
US11352341B2 (en) 2022-06-07
US20210139459A1 (en) 2021-05-13
EA202091450A1 (ru) 2021-01-14
EP3746072A1 (en) 2020-12-09
WO2019148161A1 (en) 2019-08-01
PH12020551155A1 (en) 2021-06-07
JP2021512161A (ja) 2021-05-13
SG11202006748RA (en) 2020-08-28
TW201940166A (zh) 2019-10-16
BR112020015405A2 (pt) 2020-12-08
AU2019211491A1 (en) 2020-07-30
MX2020007959A (es) 2020-09-18

Similar Documents

Publication Publication Date Title
JP6490215B2 (ja) サイクリン依存性キナーゼ(cdk)阻害剤としての2−h−インダゾール誘導体およびその治療上の使用
JP7337395B2 (ja) Cdk4およびcdk6阻害剤としての2h-インダゾール誘導体およびその治療上の使用
CN115803325B (zh) 一种egfr抑制剂及其制备方法和应用
JP7058636B2 (ja) サイクリン依存性キナーゼ7(cdk7)の阻害剤
CN105461695B (zh) 嘧啶或三嗪衍生物及其制备方法和用途
JP6691281B2 (ja) Egfr阻害薬、およびそれらの製造および応用
JP2022547294A (ja) キナーゼ阻害剤としての3,5-ジ置換ピラゾール化合物およびその応用
TWI669300B (zh) 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途
TWI710554B (zh) 新穎苯并咪唑化合物及其醫藥用途
CN112313207A (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
CN111499613B (zh) N-甲酰胺衍生物、其制备方法及其在医药上的用途
CN113574057A (zh) 杂芳基衍生物及包含其作为活性成分的药物组合物
OA19873A (en) 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof.
HK40034278A (en) 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
CN120435458A (zh) 取代的喹啉作为改进的nf-kb诱导激酶(nik)抑制剂
CN118221696A (zh) 含有n-甲基哌嗪结构的嘧啶杂环类化合物及其制备方法和应用
OA18720A (en) 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200826

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid